Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus XHANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus XHANCE.
KENALOG IN ORABASE vs XHANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
XHANCE (fluticasone propionate) is an anti-inflammatory corticosteroid that inhibits multiple inflammatory cell types and mediators (e.g., histamine, leukotrienes, cytokines) involved in nasal and sinus inflammation. It reduces nasal polyp size and nasal congestion.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
1 spray (93 mcg fluticasone propionate) per nostril twice daily (total daily dose 372 mcg). Intranasal route.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Terminal half-life is approximately 2-3 hours; short half-life supports twice-daily dosing for sustained local effect.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% of the dose as unchanged drug; fecal excretion is minimal.
Category C
Category C
Corticosteroid
Corticosteroid